Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utility of Sortilin as a Biomarker of Restenosis After Lower Extremity Endovascular Revascularization in a Cohort of Diabetic Patients With Peripheral Artery Disease and Chronic Limb-threatening Ischemia

NCT05759130 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT05759130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utility of Sortilin as a Biomarker of Restenosis After Lower Extremity Endovascular Revascularization in a Cohort of Diabetic Patients With Peripheral Artery Disease and Chronic Limb-threatening Ischemia
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Overall status
Unknown status
Start date
October 24, 2019
Completion date
October 31, 2024
Enrollment
207 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral artery disease